Interferon plus chemotherapy for primary treatment of ovarian cancer

Lancet

Volumn 355, Issue 9223, 2000, Pages 6-7

  Berek, J S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

CANCER SURVIVAL; FATIGUE; FEMALE; HUMAN; LETHARGY; NOTE; OVARY CANCER; PRIORITY JOURNAL; ARTICLE; CARCINOMA; CELL DIVISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL DIVISION; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON TYPE II; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034220346     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(00)02422-3     Document Type: Note

References (21)

1. JS Berek Epithelial ovarian cancer JS Berek NF Hacker Practical gynecologic oncology 3rd ed. 2000 Lippincott, Williams & Wilkins Philadelphia 457 522
2. P Allavena F Peccatori D Maggioni Intraperitoneal recombinant g-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells Cancer Res 50 1990 7318 7323
3. A Nehme AM Julia S Jozan C Chevreau R Bugat P Canal Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines Eur J Cancer 30A 1994 550 575
4. T Saito ME Berens CE Welander Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay Cancer Res 46 1986 1142 1147
5. M Markman JS Berek Intraperitoneal administration of the biologic agents tumor necrosis factor, gamma-interferon and interleukin-2 Int J Gynecol Cancer 2 suppl 1 1992 30 34
6. JS Berek NF Hacker A Lichtenstein Intraperitoneal recombinant α-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Cancer Res 45 1985 4447 4453
7. JS Berek Intraperitoneal adoptive immunotherapy for peritoneal cancer J Clin Oncol 10 1990 1610 1612
8. JS Berek Intraperitoneal immunotherapy for ovarian cancer with alpha interferon Eur J Cancer 28A 1992 719 721
9. JS Berek C Welander JC Schink H Grossberg FJ Montz A Zigelboim J Phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer Gynecol Oncol 40 1991 237 243
10. JS Berek M Markman JA Blessing Intraperitoneal α-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group Study Gynecol Oncol 74 1999 48 52
11. JS Berek M Markman B Stonebraker Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study Gynecol Oncol 75 1999 10 14
12. M Nardi F Cognetti CF Pollera Intraperitoneal recombinant alpha 2-interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer: a phase II study J Clin Oncol 8 1991 1036 1041
13. PHB Willemse EGE deVries NH Mulder Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer Eur J Clin Oncol 26 1991 353 358
14. R D'Acquisto M Markman T Hakes S Rubin W Hoskins JL Lewis A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma J Clin Oncol 6 1988 689 695
15. E Pujade-Lauraine JP Guastalla N Colombo Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy J Clin Oncol 14 1996 343 350
16. N Colombo F Peccatori C Paganin Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy Int J Cancer 51 1992 42 46
17. G Windbichler H Hausmaninger W Stummvoll Interferongamma in the first-line therapy of ovarian cancer: a randomized phase III trial Br J Cancer 82 2000 1138 1144
18. C Marth E Muller-Holzner E Greiter γ-interferon reduces expression of the protooncogen c-erbB-2 in human ovarian carcinoma cells Cancer Res 50 1990 7037 7041
19. C Marth AG Zeimet M Herold Different effects of interferons, interleukin-1b and tumor necrosis factor-a in normal (OSE) and malignant human ovarian epithelial cells Int J Cancer 67 1996 826 830
20. C Marth M Widschwendter J Kaern Cisplatin resistance is associated with reduced interferon-g-sensitivity and incrased HER-2 expression in cultured ovarian cancer cells Br J Cancer 76 1997 1328 1332
21. DG Duda M Sunamura L Lozonschi Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12 Cancer Res 60 2000 1111 1116